The progressive disease status of MTC was appraised in two studies by measuring the doubling time Ctn and CEA, with a cut-off of 24 months and imaging techniques to measure the variation in the size of lesions following RECIST criteria. The gene discussed is CEACAM5; the disease is medullary thyroid gland carcinoma.